The Technical Analyst
Select Language :
Celldex Therapeutics Inc [CLDX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Celldex Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Celldex Therapeutics Inc is listed at the  Exchange

0.43% $41.97

America/New_York / 28 mar 2024 @ 16:00


Celldex Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 2 703.74 mill
EPS: -2.92
P/E: -14.37
Earnings Date: May 02, 2024
SharesOutstanding: 64.42 mill
Avg Daily Volume: 0.958 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -14.37 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.44x
Company: PE -14.37 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-5.08
(-112.11%) $-47.05
Date: 2024-03-28
Expected Trading Range (DAY)

$ 39.20 - 44.61

( +/- 6.46%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-13 Jimenez Freddy A. Buy 20 000 Common Stock
2024-02-13 Jimenez Freddy A. Buy 4 166 Common Stock
2024-02-13 Jimenez Freddy A. Sell 4 166 Incentive Stock Option (Right to Buy)
2024-02-13 Jimenez Freddy A. Sell 20 000 Incentive Stock Option (Right to Buy)
2024-01-02 Martin Samuel Bates Buy 10 750 Common Stock
INSIDER POWER
74.77
Last 97 transactions
Buy: 2 900 849 | Sell: 507 801

Forecast: 16:00 - $41.97

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $41.97
Forecast 2: 16:00 - $41.97
Forecast 3: 16:00 - $41.97
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $41.97 (0.43% )
Volume 0.510 mill
Avg. Vol. 0.958 mill
% of Avg. Vol 53.25 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Celldex Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Celldex Therapeutics Inc

RSI

Intraday RSI14 chart for Celldex Therapeutics Inc

Last 10 Buy & Sell Signals For CLDX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$37.40N/AActive
Profile picture for
            Celldex Therapeutics Inc

CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Last 10 Buy Signals

Date Signal @
ARBUSDMar 28 - 17:391.680
BONDUSDMar 28 - 17:395.11
1INCHUSDMar 28 - 17:390.600
RUNEUSDMar 28 - 17:38$9.34
VRXUSDMar 28 - 17:3465.45
CTXUSDMar 28 - 17:344.90
STORJUSDMar 28 - 17:32$0.828
WHITEUSDMar 28 - 17:186 080.71
CGLDUSDMar 28 - 17:181.311
RBNUSDMar 28 - 17:151.620

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.